CURRENT APPROACHES IN CANCER IMMUNOTHERAPY

tibbibiyolojiozel-3-2-25kapak

Epigenetic Approaches in Cancer Immunotherapy

Gülçin Miyase SÖNMEZa , Melis BEKTAŞa , Selami Koçak TOPRAKa
aAnkara University Faculty of Medicine, Department of Hematology, Ankara, Türkiye

Sönmez GM, Bektaş M, Toprak SK. Epigenetic approaches in cancer immunotherapy. Sunguroğlu A, ed. Current Approaches in Cancer Immunotherapy. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.48-52.

ABSTRACT
The definition of epigenetics is reversible modifications that can cause changes in gene expression without altering the DNA sequence. Epigenetics plays a significant role in normal physiological functions and biological development, as well as in the pathogenesis of some diseases such as cancer, cardiovascular, metabolic and neurological diseases. The emergence of dynamic epigenetic changes plays an important role in the development of cancer as a chronic process. Epigenetic abnormalities are effective in tumor initiation, progression, chemoresistance and immune regulation. Targeting cancer-associated epigenetic modifications is considered an effective treatment option. We aim to highlight the significance of epigenetics in both cancer development and treatment.

Keywords: Epigenetic modifications; DNA methylation; immunotherapy

Referanslar

  1. Waddington CH. The epigenotype. 1942. Int J Epidemiol. 2012;41(1):10-3. [Crossref]
  2. Nanney DL. Epigenetic Control Systems. Proc Natl Acad Sci U S A. 1958;44(7):712-7. [Crossref]  [PubMed]  [PMC]
  3. Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79. [Crossref]  [PubMed]  [PMC]
  4. Topart C, Werner E, Arimondo PB. Wandering along the epigenetic timeline. Clin Epigenetics. 2020;12(1):97. [Crossref]  [PubMed]  [PMC]
  5. Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, Sun Y, Peng A. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28. [Crossref]  [PubMed]  [PMC]
  6. Pathak A, Tomar S, Pathak S. Epigenetics and Cancer: A Comprehensive Review. Asian Pacific Journal of Cancer Biology. 2024;8(1):75–89. [Crossref]
  7. Gu M, Ren B, Fang Y, Ren J, Liu X, Wang X, et al. Epigenetic regulation in cancer. MedComm (2020). 20245(2):e495. [Crossref]  [PubMed]  [PMC]
  8. Tulsyan S, Aftab M, Sisodiya S, Khan A, Chikara A, Tanwar P, et al. Molecular basis of epigenetic regulation in cancer diagnosis and treatment. Front Genet. 2022;13:885635. [Crossref]  [PubMed]  [PMC]
  9. Bennett RL, Licht JD. Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol. 2018;58:187-207. [Crossref]  [PubMed]  [PMC]
  10. Yang AY, Kim H, Li W, Kong ANT. Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers Graphical Abstract HHS Public Access. Curr Top Med Chem. 2016;16(7):697–713. [Crossref]  [PubMed]  [PMC]
  11. Keshari S, Barrodia P, Singh AK. Epigenetic Perspective of Immunotherapy for Cancers. Cells. 2023;12(3):365. [Crossref]  [PubMed]  [PMC]
  12. Parab A, Kumar Bhatt L, Omri A. Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. Biomedicines. 2023;11(1):169. [Crossref]  [PubMed]  [PMC]
  13. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, ET AL. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65(14):6305-11. [Crossref]
  14. Kondo Y. Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers. Yonsei Med J. 2009;50:455–63. [Crossref]  [PubMed]  [PMC]
  15. Zhou J, Yao Y, Shen Q, Li G, Hu L, Zhang X. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. J Cancer Res Clin Oncol. 2017;143:1371–80. [Crossref]
  16. Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, ET AL. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2012;98:1196–205. [Crossref]  [PubMed]  [PMC]
  17. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170(1):142-157.e19. [Crossref]  [PubMed]  [PMC]
  18. Jiang S. Tet2 at the interface between cancer and immunity. Commun. Biol. 2020;3:667. [Crossref]  [PubMed]  [PMC]
  19. Xu YP, Lv L, Liu Y, Smith MD, Li WC, Tan XM, et al. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest. 2019;129(10):4316-31. [Crossref]  [PubMed]  [PMC]
  20. Tao L, Zhou Y, Luo Y, Qiu J, Xiao Y, Zou J, et al. Epigenetic regulation in cancer therapy: from mechanisms to clinical advances. MedComm – Oncology. 2024;3(1):e59. [Crossref]
  21. Cho H, Son WC, Lee YS, Youn EJ, Kang CD, Park YS, et al. Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells. Molecules. 2021;26(13):3952. [Crossref]  [PubMed]  [PMC]
  22. Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836-50. [Crossref]  [PubMed]  [PMC]
  23. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, et al. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep. 2018;23(11):3262-74. [Crossref]  [PubMed]  [PMC]
  24. Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):210. [Crossref]  [PubMed]  [PMC]